Wang et al. Propensity score matched cohort study. 63,302 individuals. Colchicine associated lower risk of THR/TKR, HR 0.87. @RheumNow #ACR24 Abstr#2557 https://t.co/UUU3Tm67ML https://t.co/uKi0e8E7HV

• The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a …
• https://x.com/RichardPAConway/status/1858572127508877503/photo/1

Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3

• Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Ope…
• https://x.com/RichardPAConway/status/1858557782405833156/photo/1

Ahmadzay et al. Real world secukinumab in PsA data in 1202 patients. Smokers/ex-smokers have 30% lower treatment retention. But if they maintain treatment, appear to respond equally well. BMI no effect. @RheumNow #ACR24 Abstr#2350 https://t.co/XVPmEBbRu8 https://t.co/QyJirWRKvq

• Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data f…
• https://x.com/RichardPAConway/status/1858553252964692082/photo/1

US biosimilar exp Interchangeable biosimilar - can substitute for reference product wo consulting MD Primary endpt: pharmacokinetic data 61 approved biosimilars @RheumKay: “pts should share in financial benefits” Currently 5-87% discount #PBMReform @ACRheumDC @RheumNow #ACR24 https://t.co/RqwbZalZko

• https://x.com/ericdeinmd/status/1858547083017363622/photo/1
• https://x.com/ericdeinmd/status/1858547083017363622/photo/1
• https://x.com/ericdeinmd/status/1858547083017363622/photo/1

Triboulet et al. JAKi in RA-ILD. 42 patients. Stability of PFTs over median 21 months. HRCT stable in 62%. Progressive ILD on HRCT in 19%. @RheumNow #ACR24 Abstr#2249 https://t.co/PY9BrCfNHc https://t.co/r8fIgrjyDu

• Assessment of Interstitial Lung Disease in Rheumatoid Arthritis Patients Treate…
• https://x.com/RichardPAConway/status/1858548723107668184/photo/1

Important study in SLE: out of 590 pts with pericarditis, 20% had recurrence w/in 1 year Higher in early dx, younger pts, higher dx activity, & pred exposure Is prednisone risk confounding by indication? Or causative? #ACR24 @RheumNow @andreafava Abstr#2372 https://t.co/Seyi4F6weY

• https://x.com/EBRheum/status/1858542179917951436/photo/1
• https://x.com/EBRheum/status/1858542179917951436/photo/1

@DianeLacaille Canadian biosimilar exp Biosimilar transition v originator controls x2 yrs Weighted model: no decr in ETN biosimilar discontinuation v originator. IFX shows slight decrease - NOT statistical signif Safety- no difference, slight incr rheum visits @RheumNow #ACR24 https://t.co/0GMfLAyzOo

• https://x.com/ericdeinmd/status/1858542595636392007/photo/1

Updated ACR guidelines on management of lupus nephritis (LN). Consider early biopsy. Focus on triple therapy in LN. From the panel discussion, Tacrolimus can be an alternative to CNI (Voclosporin) where there is no access to this. Manage comorbidities such as CV risk, bone… https://t.co/4R02YnRXDP https://t.co/3J7YcF5ucQ

• https://x.com/i/web/status/1858545592370188704
• https://x.com/synovialjoints/status/1858545592370188704/photo/1

Galloway et al. 117,050 individuals. VTE risk in RA consistently increased, irrespective of age, sex, BMI. Risk VTE 46% higher in RA! @RheumNow #ACR24 Abstr#1901 https://t.co/SQPcPiBeF2 https://t.co/BQkERUsGlL

• Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid…
• https://x.com/RichardPAConway/status/1858545954540175534/photo/1